Shortened progression free and overall survival to immune-checkpoint inhibitors in BRAF-, RAS- and NF1- (“Triple”) wild type melanomasPhilipp Jansen, Klaus Griewank, Georg Lodde et al.|European Journal of Cancer|2024Cited by 4